【摘要】 目的 　研究小儿CD7抗原阳性急性髓系白血病 (CD7+AML)的临床生物学特征及治疗效果。方法 　对 55例初治小儿AML进行细胞形态学、免疫表型、多药耐药P糖蛋白 (P1 70 )检测 ,临床观察 ,并常规采用HAE方案诱导治疗 ,判定疗效。结果2 3例CD7+小儿AML在FAB分型中以M2 、M5 多见。M3 中无一例CD7抗原表达 ,将CD7+与CD7-两组小儿AML进行对比 ,CD7+AML具有肝脏明显增大 (P <0 0 0 5) ,外周血白细胞数、原始细胞比例及P -糖蛋白表达增高等特点 (P <0 0 0 5,P <0 0 1及P <0 0 5) ,且年龄偏低 ,中位数年龄 7 6岁 (P <0 0 1 ) ,治疗效果差 ,完全缓解率4 3% ,达首次缓解中位时间为 55 5天。结论 　小儿CD7+AML具有独特的临床生物学特征 ,常表达P -糖蛋白 ,临床症状重 ,治疗效果差 ,完全缓解率低 (P <0 0 5) ,达首次缓解时间长 (P <0 0 5)。更多还原

【Abstract】 Objective To study clinical characteristics an d therapeutic effects on CD₇ positive child acute myeloid leukemia（CD₇+AML） .Methods Morphology, immunophenotype, P-glycoprotein were ex amined in 55 previously untreated CD₇+AML patients. Routine chemotherapeutic regimen HAE was used for the treatments.Results 23 cases exp ressed CD₇+, CD₇+AML patients had a significantly higher incidence of pe rip heral leukocytosis（P<0.05） and blasts（P<0.05） lower median age 7.6 （ P<0.01） and hepatomegaly （P<0.005） and FAB M₂?M₅ subtype were ass ociated （without M₃） with P-glycoprotein expression 43% of CD₇+ AML achiev ed complete remission with a median time to CR of 55.5 days. Conclusio ns CD₇+ AML might constitute a distinct biologic and clinical d is ease entity. Patients with CD₇+ AML are usually P-glycoprotein positive. The se patients had a lower CR rate and a shorter remission duration. Our results su ggest that CD₇ expression on AML cells can be regarded as a prognostic risk fa ctor in AML. <更多还原